KURASHINA RIYOU

Profiles

Profiles

• 氏名

  KURASHINA RIYOU

Affiliation

• Department of Urology

Research achievements

Published Papers

Original paper
• Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma., Kurashina Ryo;Ando Kiyohiro;Inoue Masaharu;Izumi Keita;Maruyama Riko;Mitani Kouki;Takenobu Hisanori;Haruta Masayuki;Iizuka Toshihiko;Kamijo Takehiko;Kageyama Yukio, Anticancer research, 42(2), 1131-1136, Feb. 2022

  DOIPermalink
• Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma., Kurashina Ryo;Ando Kiyohiro;Inoue Masaharu;Maruyama Riko;Mitani Kouki;Takenobu Hisanori;Haruta Masayuki;Onuki Ritsuko;Matsuoka Yoh;Kamijo Takehiko;Kageyama Yukio, Cancer diagnosis & prognosis, 3(2), 230-235, 03 Mar. 2023

  DOI
• Transperitoneal laparoscopic umbilical resection of urachal remnants: a feasible surgical method., Yuki Hideo;Ohkubo Naoya;Kurashina Ryo;Sakamoto Kazumasa;Suzuki Issei;Takei Kohei;Betsunoh Hironori;Nukui Akinori;Yashi Masahiro;Kamai Takao, BMC urology, 23(1), 57, 04 Apr. 2023

  DOI
• Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma., Ando Kiyohiro;Kurashina Ryo;Motoi Noriko;Iizuka Toshihiko;Inoue Masaharu;Maruyama Riko;Mitani Kouki;Takenobu Hisanori;Haruta Masayuki;Onuki Ritsuko;Matsuoka Yoh;Kamijo Takehiko;Kageyama Yukio, Biochemical and biophysical research communications, 676, 165-170, 26 Jul. 2023

  DOI
• 36(臨増), 849, Aug. 2023
• 58(1), np48, Jan. 2024

Case report
• Utility of whole-body diffusion-weighted magnetic resonance imaging in the management of treatment-related neuroendocrine prostate cancer., Kurashina Ryo;Kijima Toshiki;Okazaki Akihito;Fuchizawa Hirotaka;Suzuki Issei;Sakamoto Kazumasa;Betsunoh Hironori;Fukabori Yoshitatsu;Yashi Masahiro;Kamai Takao, IJU case reports, 4(2), 69-73, Mar. 2021

  DOIPermalink
• A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab Treatment for Bladder Cancer., Sekiguchi Yasunobu;Nishimura You;Kanda Hiroaki;Kawamura Machiko;Kobayashi Kazuhiko;Mitani Koki;Kurashina Ryo;Ikeda Riko;Inoue Masaharu;Matsuoka Yoh;Kageyama Yukio;Akaba Yuki;Kobayashi Hirofumi, Gan to kagaku ryoho. Cancer & chemotherapy, 50(9), 985-992, Sep. 2023
• A case of adrenal undifferentiated pleomorphic sarcoma with tertiary lymphoid structures responded to pembrolizumab., Kokubun Hidetoshi;Kijima Toshiki;Takada-Owada Atsuko;Mamiya Daisuke;Kurashina Ryo;Okubo Naoya;Uematsu Toshitaka;Takei Kohei;Ishida Kazuyuki;Kamai Takao, IJU case reports, 6(6), 440-444, 14 Sep. 2023

  DOI
• Increased expression of ATP-binding cassette transporters in enfortumab vedotin-resistant urothelial cancer., Kotono Mariko;Kijima Toshiki;Takada-Owada Atsuko;Okubo Naoya;Kurashina Ryo;Kokubun Hidetoshi;Uematsu Toshitaka;Takei Kohei;Ishida Kazuyuki;Kamai Takao, IJU case reports, 7(2), 173-176, 29 Jan. 2024

  DOI
• 50(9), 985-992, Sep. 2023